[{"edinetCode":"E00976","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2502.0,"averageTemporaryStaff":582.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":10491000.0,"sharesOwendPercent":0.2749,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":3722.9,"equityRatio":0.62,"cashAndCashEquivalents":30771000000.0,"assets":221538000000.0,"currentAssets":137346000000.0,"fixedAsset":84192000000.0,"tangibleFixedAssets":77084000000.0,"intangibleFixedAssets":1444000000.0,"investmentAndOtherAssets":5662000000.0,"liabilities":83938000000.0,"currentLiabilities":54875000000.0,"shorTermDept":1600000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":29063000000.0,"bonds":20000000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5263000000.0,"netAsset":137600000000.0,"capitalStock":136062000000.0,"capital":27170000000.0,"capitalSurplus":27803000000.0,"accumulatedEarnings":87094000000.0,"treasuryStock":-6006000000.0,"valuationAndConversionAdjustments":1194000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":132428000000.0,"costOfSales":80308000000.0,"grossProfit":52119000000.0,"sgaExpenses":31485000000.0,"salaryAndBenefit":5602000000.0,"depreciationAndSGA":823000000.0,"RDExpenses":10207000000.0,"operatingIncome":20633000000.0,"nonOperatingIncome":380000000.0,"nonOperatingExpenses":456000000.0,"interestExpense":241000000.0,"ordinaryProfit":20557000000.0,"extraordinaryGain":null,"extraordinaryLoss":686000000.0,"incomeBeforeTax":19870000000.0,"incomeTaxes":3956000000.0,"netIncome":15914000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":15914000000.0,"comprehensiveIncome":16503000000.0,"eps":431.65,"dilutedEps":431.39,"dividendPerShare":null,"per":13.9,"roe":0.121,"cashFlowFromOperatingActivities":20628000000.0,"depreciationAndCashflowFromOperatingActivities":8645000000.0,"cashFlowFromInvestingActivities":-16206000000.0,"cashFlowFromFinancialActivities":-6740000000.0,"changesInCashAndCashEquivalents":-2325000000.0,"列1":"asr","submitDate":"2017\/6\/27","stockCode":4555,"accountingYear":"第69期(自　平成28年４月１日　至　平成29年３月31日)","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":3252.0,"averageTemporaryStaff":466.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":11671000.0,"sharesOwendPercent":0.2666,"outstandingShares":null,"numberOfSubsidiary":null,"bps":3982.11,"equityRatio":0.497,"cashAndCashEquivalents":39992000000.0,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":6885000000.0,"eps":273.45,"dilutedEps":273.28,"dividendPerShare":null,"per":13.0,"roe":0.068,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2018\/6\/26","stockCode":4555,"accountingYear":"第70期(自　2017年４月１日　至　2018年３月31日)","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":3131.0,"averageTemporaryStaff":438.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13135000.0,"sharesOwendPercent":0.3,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":372889000000.0,"currentAssets":184907000000.0,"fixedAsset":null,"tangibleFixedAssets":81233000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":149684000000.0,"currentLiabilities":70350000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":41184000000.0,"capitalSurplus":42849000000.0,"accumulatedEarnings":113342000000.0,"treasuryStock":-1385000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":109442000000.0,"grossProfit":null,"sgaExpenses":32380000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":14.5,"roe":null,"cashFlowFromOperatingActivities":42923000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-16820000000.0,"cashFlowFromFinancialActivities":-9513000000.0,"changesInCashAndCashEquivalents":17074000000.0,"列1":"asr","submitDate":"2019\/6\/25","stockCode":4555,"accountingYear":"第71期(自　2018年４月１日　至　2019年３月31日)","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":374893000000.0,"currentAssets":187822000000.0,"fixedAsset":null,"tangibleFixedAssets":83823000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":152131000000.0,"currentLiabilities":70036000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":41184000000.0,"capitalSurplus":42849000000.0,"accumulatedEarnings":116722000000.0,"treasuryStock":-1385000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":27232000000.0,"grossProfit":null,"sgaExpenses":7646000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":6073000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-3719000000.0,"cashFlowFromFinancialActivities":-3419000000.0,"changesInCashAndCashEquivalents":-1554000000.0,"列1":"q1r","submitDate":"2019\/8\/6","stockCode":4555,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13172000.0,"sharesOwendPercent":0.3008,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":381841000000.0,"currentAssets":186493000000.0,"fixedAsset":null,"tangibleFixedAssets":82191000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":154200000000.0,"currentLiabilities":70799000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":41199000000.0,"capitalSurplus":42863000000.0,"accumulatedEarnings":121257000000.0,"treasuryStock":-1385000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":53259000000.0,"grossProfit":null,"sgaExpenses":15758000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":15160000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-12606000000.0,"cashFlowFromFinancialActivities":-5076000000.0,"changesInCashAndCashEquivalents":-2926000000.0,"列1":"q2r","submitDate":"2019\/11\/8","stockCode":4555,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":388230000000.0,"currentAssets":192338000000.0,"fixedAsset":null,"tangibleFixedAssets":81229000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":154925000000.0,"currentLiabilities":82554000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":41199000000.0,"capitalSurplus":42863000000.0,"accumulatedEarnings":124759000000.0,"treasuryStock":-1385000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":83138000000.0,"grossProfit":null,"sgaExpenses":24013000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":17140000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-15480000000.0,"cashFlowFromFinancialActivities":-9495000000.0,"changesInCashAndCashEquivalents":-8095000000.0,"列1":"q3r","submitDate":"2020\/2\/14","stockCode":4555,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":3066.0,"averageTemporaryStaff":366.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":12434000.0,"sharesOwendPercent":0.284,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":384814000000.0,"currentAssets":191364000000.0,"fixedAsset":null,"tangibleFixedAssets":81013000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":151128000000.0,"currentLiabilities":80124000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":41199000000.0,"capitalSurplus":42863000000.0,"accumulatedEarnings":126719000000.0,"treasuryStock":-1385000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":109037000000.0,"grossProfit":null,"sgaExpenses":33375000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":13.1,"roe":null,"cashFlowFromOperatingActivities":30256000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-18173000000.0,"cashFlowFromFinancialActivities":-12747000000.0,"changesInCashAndCashEquivalents":-985000000.0,"列1":"asr","submitDate":"2020\/6\/23","stockCode":4555,"accountingYear":"第72期(自　2019年４月１日　至　2020年３月31日)","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":383446000000.0,"currentAssets":193395000000.0,"fixedAsset":null,"tangibleFixedAssets":79930000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":148088000000.0,"currentLiabilities":78489000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":41199000000.0,"capitalSurplus":42863000000.0,"accumulatedEarnings":129343000000.0,"treasuryStock":-1385000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":26318000000.0,"grossProfit":null,"sgaExpenses":8024000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":7657000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-3330000000.0,"cashFlowFromFinancialActivities":-3094000000.0,"changesInCashAndCashEquivalents":1139000000.0,"列1":"q1r","submitDate":"2020\/8\/6","stockCode":4555,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":12561000.0,"sharesOwendPercent":0.2868,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":388966000000.0,"currentAssets":199023000000.0,"fixedAsset":null,"tangibleFixedAssets":82012000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":150578000000.0,"currentLiabilities":84456000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":41219000000.0,"capitalSurplus":42883000000.0,"accumulatedEarnings":134673000000.0,"treasuryStock":-1385000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":54103000000.0,"grossProfit":null,"sgaExpenses":16110000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":13438000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-8590000000.0,"cashFlowFromFinancialActivities":-4653000000.0,"changesInCashAndCashEquivalents":-92000000.0,"列1":"q2r","submitDate":"2020\/11\/9","stockCode":4555,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0},{"edinetCode":"E00976","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":390865000000.0,"currentAssets":203034000000.0,"fixedAsset":null,"tangibleFixedAssets":82420000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":151502000000.0,"currentLiabilities":75676000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":41219000000.0,"capitalSurplus":42883000000.0,"accumulatedEarnings":138415000000.0,"treasuryStock":-1385000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":85909000000.0,"grossProfit":null,"sgaExpenses":24857000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":16457000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-14903000000.0,"cashFlowFromFinancialActivities":-8942000000.0,"changesInCashAndCashEquivalents":-7857000000.0,"列1":"q3r","submitDate":"2021\/2\/12","stockCode":4555,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00976","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":41198,"settlementDate":"2022\/3\/31","submitterName":"沢井製薬株式会社","submitterNameEnglish":"SAWAI PHARMACEUTICAL CO.,LTD.","submitterNameKana":"サワイセイヤクカブシキカイシャ","location":"大阪市淀川区宮原五丁目２番３０号","industory":"医薬品","corporateNumber":4120000000000.0}]